Online Tumor Board Simulation: Optimizing Testing and Treatment of Patients with BRAF^V600E-mutant mCRC in Community Practice  

This 60-minute self-paced (asynchronous) online tumor board will help pathologists and laboratory professionals, particularly those in community practice, gain deeper scientific knowledge and skills in diagnosing, testing, and treating patients with BRAF-mutant mCRC. Throughout the online tumor board simulation, learners will answer questions designed to help them carefully consider the nuances of each case, building their knowledge and skills related to the detection and optimal management of patients with BRAF-mutant mCRC.    

The activity offers 1.0 CME/CMLE credit. 

Faculty/Authors

Wei Jiang, MD, PhD 
Associate Professor 
Director, Translational Research/Pathology 
Shared Resource of Sidney Kimmel Cancer Center 
Thomas Jefferson University 
Philadelphia, PA  

Atrayee Basu-Mallick, MD 
Associate Professor 
Medical Oncology 
Jefferson Health/Jefferson University Hospitals 
Philadelphia, PA  

Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

CME/CMLE Credit: 1.0
Estimated Completion Time: 1.0 hour
Format: Online educational activity

Credit Designation Statement
The American Society for Clinical Pathology (ASCP) designates this on-demand enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
 
ASCP designates this on-demand enduring activity for a maximum of 1.0 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.  
 
Method of Participation
To complete the activity and receive credit, the participant must complete the online activity. CME certificates will be provided online.
 
Commercial Support
This activity is supported by educational grants from Lilly and Pfizer.   

Instructions

To claim CME/CMLE credit for the exercise, do the following:

1. Review the Technical Considerations.
2. Click Go to Content and click the first module of the course.
3. Complete the Demographic Survey.
4. Complete the Pre-Test.
5. Review the Educational Activity.
6. Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
7. Submit the course Evaluation.
8. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Upon completion of this activity, you will be able to:

• Apply NCCN guidelines for molecular testing of patients with mCRC to ensure they are appropriately testing for potential BRAF mutations at the time of diagnosis 

• Discuss importance of biomarker testing for patients with mCRC  

• Discuss clinicopathologic characteristics of BRAF-mutant mCRC  

• Discuss current and emerging treatment options for BRAF^V600E-mutant mCRC  

• Guide medical oncologists and other members of the interdisciplinary cancer care team on the diagnosis, testing, and treatment of patients with BRAF^V600E-mutant mCRC